Prospective evaluation of the PRIMARY score using [18F]PSMA-1007 PET/MRI in second-line prostate biopsies after negative MRI
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-08070-3 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Mads Ryø Jochumsen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, Aarhus, 8200 Aarhus N, Denmark. madsjoch@rm.dk. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography, Oligopeptides, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus University Hospital.
Abstract (Originalsprache)
Purpose
PSMA PET has been proposed for guiding targeted prostate biopsies. As the rate of clinically significant prostate cancer (csPCa) is positively correlated with PSA density (PSAd), a potential application for PSMA-guided biopsies may be men with negative MRI-first (PI-RADS-1-2) but increased PSAd. The PRIMARY scoring system, using the intraprostatic PSMA-pattern was developed and tested using [ 68 Ga]Ga-PSMA-11 and proposed to be universal across PSMA-ligands, however no data on [ 18 F]PSMA-1007 for biopsy guidance exists. Thus, the aim of this study was to evaluate the PRIMARY score for prostate biopsy guidance using [ 18 F]PSMA-1007 in a prospective clinical setup.
Methods
91 patients were prospectively enrolled for [ 18 F]PSMA-1007 PET/MRI, 86 of these for biopsy guidance after negative MRI or non-csPCa biopsies from PI-RADS 3–5 lesions and persistent suspicion of csPCa. Transperineal MRI/ultrasound fusion target biopsies were performed predominantly from PRIMARY 3–5 lesions. Nine patients with PRIMARY 1–2 did not undergo target biopsies. CsPCa was defined as ISUP grade ≥ 2.
Results
In a per patient analysis, 23.3% (20/86) were diagnosed with csPCa. In line with previous studies, the rate of csPCa increased with higher PRIMARY score in a per lesion analysis, constituting 0% (0/1), 0% (0/8), 7.2% (7/97), 60% (15/25), and 60% (6/10) for PRIMARY 1, 2, 3, 4, and 5 lesions, respectively. The 7.2% PRIMARY-3 lesions containing csPCa exhibited common characteristics such as anterior location or lack of well-defined separation from the peripheral zone.
Conclusion
We evaluated the PRIMARY score for use with [¹⁸F]PSMA-1007 and identified benign features and potential “red flags” for PRIMARY-3 lesions. We found csPCa in 23.3% of patients with negative MRI or non-csPCa biopsies from PI-RADS 3–5 lesions and persistent suspicion of csPCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, Aarhus, 8200 Aarhus N, Denmark. madsjoch@rm.dk.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. madsjoch@rm.dk.
- Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Nuclear Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, Aarhus, 8200 Aarhus N, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Förderung
- Aarhus University Hospital
Zitieren
APA
Jochumsen, M. R., Medrud, L., Dias, A. H., Pedersen, M. A., Stilling, C., Bouchelouche, K., Iversen, P., Fledelius, J., Tolbod, L. P., Grønnemark, L. F., Vind-Kezunovic, S., Andersen, M. H., & Berg, K. D. (2026). Prospective evaluation of the PRIMARY score using [18F]PSMA-1007 PET/MRI in second-line prostate biopsies after negative MRI. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08070-3
Vancouver
Jochumsen MR, Medrud L, Dias AH, Pedersen MA, Stilling C, Bouchelouche K, et al. Prospective evaluation of the PRIMARY score using [18F]PSMA-1007 PET/MRI in second-line prostate biopsies after negative MRI. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08070-3
BibTeX
@article{Jochumsen2026,
author = {Jochumsen, Mads Ryø and Medrud, Lise and Dias, André H and Pedersen, Mette Abildgaard and Stilling, Christina and Bouchelouche, Kirsten and Iversen, Peter and Fledelius, Joan and Tolbod, Lars Poulsen and Grønnemark, Louise Forsmann and Vind-Kezunovic, Stefan and Andersen, Morten Heebøll and Berg, Kasper Drimer},
title = {Prospective evaluation of the PRIMARY score using [18F]PSMA-1007 PET/MRI in second-line prostate biopsies after negative MRI},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-08070-3}
}
EUVIMED